Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C. & Lordick, F. Gastric cancer. Lancet 396, 635–648 (2020).

Article  CAS  PubMed  Google Scholar 

Kang, Y. K. et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 23, 234–247 (2022).

Article  CAS  PubMed  Google Scholar 

Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lordick, F. et al. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1005–1020 (2022).

Article  CAS  PubMed  Google Scholar 

Nagatsuma, A. K. et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 18, 227–238 (2015).

Article  CAS  PubMed  Google Scholar 

Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y. & Shitara, K. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat. Rev. Clin. Oncol. 18, 473–487 (2021).

Article  PubMed  Google Scholar 

Shitara, K. et al. Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer. Nature 603, 942–948 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yeong, J. et al. Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy. Gastric Cancer 25, 741–750 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shitara, K. et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401, 1655–1668 (2023).

Article  CAS  PubMed  Google Scholar 

Shah, M. A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat. Med. 29, 2133–2141 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian, Y. Y. et al. A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101. J. Clin. Oncol. 41, (Suppl. 16), Abstr. TPS4176 (2023).

Article  Google Scholar 

Xu, R.-H. et al. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors. J. Clin. Oncol. 41, (Suppl. 4), Abstr. 352 (2023).

Article  Google Scholar 

Barbier, A. J., Jiang, A. Y., Zhang, P., Wooster, R. & Anderson, D. G. The clinical progress of mRNA vaccines and immunotherapies. Nat. Biotechnol. 40, 840–854 (2022).

Article  CAS  PubMed  Google Scholar 

Sahin, U. et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin. Cancer Res. 14, 7624–7634 (2008).

Article  CAS  PubMed  Google Scholar 

Tsukita, S., Itoh, M., Nagafuchi, A., Yonemura, S. & Tsukita, S. Submembranous junctional plaque proteins include potential tumor suppressor molecules. J. Cell Biol. 123, 1049–1053 (1993).

Article  CAS  PubMed  Google Scholar 

Zihni, C., Mills, C., Matter, K. & Balda, M. S. Tight junctions: from simple barriers to multifunctional molecular gates. Nat. Rev. Mol. Cell Biol. 17, 564–580 (2016).

Article  CAS  PubMed  Google Scholar 

Schneeberger, E. E. & Lynch, R. D. Structure, function, and regulation of cellular tight junctions. Am. J. Physiol. 262, L647–L661 (1992).

CAS  PubMed  Google Scholar 

Gunzel, D. & Yu, A. S. Claudins and the modulation of tight junction permeability. Physiol. Rev. 93, 525–569 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Gumbiner, B. M. Breaking through the tight junction barrier. J. Cell Biol. 123, 1631–1633 (1993).

Article  CAS  PubMed  Google Scholar 

Anderson, J. M. & Van Itallie, C. M. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 269, G467–G475 (1995).

CAS  PubMed  Google Scholar 

Staehelin, L. A. Further observations on the fine structure of freeze-cleaved tight junctions. J. Cell Sci. 13, 763–786 (1973).

Article  CAS  PubMed  Google Scholar 

Tsukita, S. & Furuse, M. Pores in the wall: claudins constitute tight junction strands containing aqueous pores. J. Cell Biol. 149, 13–16 (2000).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K. & Tsukita, S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J. Cell Biol. 141, 1539–1550 (1998).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morin, P. J. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res. 65, 9603–9606 (2005).

Article  CAS  PubMed  Google Scholar 

Niimi, T. et al. Claudin-18, a novel downstream target gene for the T/EBP/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing. Mol. Cell Biol. 21, 7380–7390 (2001).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Türeci, O. et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene 481, 83–92 (2011).

Article  PubMed  Google Scholar 

Sahin, U. et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann. Oncol. 32, 609–619 (2021).

Article  CAS  PubMed  Google Scholar 

Jovov, B. et al. Claudin-18: a dominant tight junction protein in Barrett’s esophagus and likely contributor to its acid resistance. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G1106–G1113 (2007).

Article  CAS  PubMed  Google Scholar 

Hayashi, D. et al. Deficiency of claudin-18 causes paracellular H+ leakage, up-regulation of interleukin-1beta, and atrophic gastritis in mice. Gastroenterology 142, 292–304 (2012).

Article  CAS  PubMed  Google Scholar 

Hewitt, K. J., Agarwal, R. & Morin, P. J. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6, 186 (2006).

Article  PubMed  PubMed Central  Google Scholar 

Jun, K. H., Kim, J. H., Jung, J. H., Choi, H. J. & Chin, H. M. Expression of claudin-7 and loss of claudin-18 correlate with poor prognosis in gastric cancer. Int. J. Surg. 12, 156–162 (2014).

Article  PubMed  Google Scholar 

Chen, X. et al. Clinicopathological significance of claudin 4 expression in gastric carcinoma: a systematic review and meta-analysis. Oncol. Targets Ther. 27, 3205–3212 (2016).

Google Scholar 

Park, J. Y. et al. Up-regulated claudin 7 expression in intestinal-type gastric carcinoma. Oncol. Rep. 18, 377–382 (2007).

CAS  PubMed  Google Scholar 

Kohmoto, T. et al. Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer. Gastric Cancer 23, 403–417 (2020).

Article  CAS  PubMed  Google Scholar 

Hedrick, L., Cho, K. R. & Vogelstein, B. Cell adhesion molecules as tumour suppressors. Trends Cell Biol. 3, 36–39 (1993).

Article  CAS  PubMed  Google Scholar 

Resnick, M. B., Konkin, T., Routhier, J., Sabo, E. & Pricolo, V. E. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod. Pathol. 18, 511–518 (2005).

Article  CAS  PubMed  Google Scholar 

Al Moustafa, A. E. et al. Identif